Frequent occult infection with cytomegalovirus in cardiac transplant recipients despite antiviral prophylaxis

Journal of Clinical Microbiology

Volumn 45, Issue 6, 2007, Pages 1804-1810

  Potena, Luciano ^a,c   Holweg, Cecile T J ^a   Vana, Marcy L ^a   Bashyam, Leena ^a   Rajamani, Jaya ^a   McCormick, A Louise ^a,b   Cooke, John P ^a   Valantine, Hannah A ^a   Mocarski, Edward S ^a,b  

^a STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b EMORY UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c UNIVERSITY OF BOLOGNA   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

CYCLOSPORIN; CYTOMEGALOVIRUS ANTIBODY; DACLIZUMAB; GANCICLOVIR; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; PREDNISONE; RAPAMYCIN; VALGANCICLOVIR; VIRUS DNA;

ADULT; ARTICLE; CARDIAC GRAFT REJECTION; CYTOMEGALOVIRUS INFECTION; DONOR; FEMALE; GRAFT RECIPIENT; HEART MUSCLE BIOPSY; HEART TRANSPLANTATION; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; KAPLAN MEIER METHOD; MAJOR CLINICAL STUDY; MALE; PERIPHERAL BLOOD MONONUCLEAR CELL; POLYMERASE CHAIN REACTION; PREVALENCE; PRIORITY JOURNAL; PROPHYLAXIS; STATISTICAL ANALYSIS; VIRUS DETECTION; VIRUS REACTIVATION;

ADULT; ANTIVIRAL AGENTS; CHEMOPREVENTION; CYTOMEGALOVIRUS; CYTOMEGALOVIRUS INFECTIONS; DNA, VIRAL; FEMALE; GANCICLOVIR; HEART TRANSPLANTATION; HUMANS; IMMUNOGLOBULINS, INTRAVENOUS; IMMUNOLOGIC FACTORS; INCIDENCE; MALE; MIDDLE AGED; VIREMIA;

CYTOMEGALOVIRUS;

EID: 34250660941     PISSN: 00951137     EISSN: None     Source Type: Journal    
DOI: 10.1128/JCM.01362-06     Document Type: Article

References (25)

1. Beniaminovitz, A., S. Itescu, K. Lietz, M. Donovan, E. M. Burke, B. D. Groff, N. Edwards, and D. M. Mancini. 2000. Prevention of rejection in cardiac transplantation by blockade of the interleukin-2 receptor with a monoclonal antibody. N. Engl. J. Med. 342:613-619.
2. Billingham, M. E., N. R. Cary, M. E. Hammond, J. Kemnitz, C. Marboe, H. A. McCallister, D. C. Snovar, G. L. Winters, A. Zerbe, et al. 1990. A working formulation for the standardization of nomenclature in the diagnosis of heart and lung rejection. J. Heart Transplant. 9:587-593.
3. Emery, V. C., A. F. Hassan-Walker, A. K. Burroughs, and P. D. Griffiths. 2002. Human cytomegalovirus (HCMV) replication dynamics in HCMV-naive and -experienced immunocompromised hosts. J. Infect. Dis. 185:1723-1728.
4. Freeman, R. B., C. Paya, M. D. Pescovitz, A. Humar, E. Dominguez, K. Washburn, E. Blumberg, B. Alexander, and N. Heaton. 2004. Risk factors for cytomegalovirus viremia and disease developing after prophylaxis in high-risk solid-organ transplant recipients. Transplantation 78:1765-1773.
5. Gerna, G., M. Zavattoni, E. Percivalle, D. Zella, M. Torsellini, and M. G. Revello. 1996. Diagnosis of human cytomegalovirus infections in the immunocompromised host. Clin. Diagn. Virol. 5:181-186.
6. Gerna, G., D. Zipeto, E. Percivalle, M. Parea, M. G. Revello, R. Maccario, G. Peri, and G. Milanesi. 1992. Human cytomegalovirus infection of the major leukocyte subpopulations and evidence for initial viral replication in polymorphonuclear leukocytes from viremic patients. J. Infect. Dis. 166:1236-1244.
7. Hart, G. D., and C. V. Paya. 2001. Prophylaxis for CMV should now replace pre-emptive therapy in solid organ transplantation. Rev. Med. Virol. 11:73-81.
8. Jarvis, M., and J. Nelson. 2007. HCMV: molecular basis of persistence and latency, p. 761-775. In A. M. Arvin, E. S. Mocarski, P. Moore, R. Whitley, K. Yamanishi, G. Campadelli-Fiume, and B. Roizman (ed.), Human herpesviruses: biology, therapy and immunoprophylaxis. Cambridge University Press, Cambridge, United Kingdom.
9. Jothikumar, N., T. L. Cormeans, V. R. Hill, X. Lu, M. D. Sobsey, and D. D. Erdman. 2005. Quantitative real-time PCR assays for detection of human adenoviruses and identification of serotypes 40 and 41. Appl. Environ. Microbiol. 71:3131-3136.
10. Koskinen, P., K. Lemstrom, C. Bruggeman, I. Lautenschlager, and P. Hayry. 1994. Acute cytomegalovirus infection induces a subendothclial inflammation (endothelialitis) in the allograft vascular wall. A possible linkage with enhanced allograft arteriosclerosis. Am. J. Pathol. 144:41-50.
11. Merigan, T. C., D. G. Renlund, S. Keay, M. R. Bristow, V. Starnes, J. B. O'Connell, S. Resta, D. Dunn, P. Gamberg, R. M. Ratkovee, et al. 1992. A controlled trial of ganciclovir to prevent cytomegalovirus disease after heart transplantation. N. Engl. J. Med. 326:1182-1186.
12. Mocarski, E. S., Jr., G. Hahn, K. L. White, J. Xu, B. Slobedman, L. Hertel, S. A. Aguirre, and S. Noda. 2005. Myeloid cell recruitment and function in pathogenesis and latency, p. 465-482. In M. J. Reddehase (ed.), Cytomegaloviruses: pathogenesis, molecular biology, and infection control. Caister Scientific Press, Norfolk, United Kingdom.
13. Paya, C. V., and R. R. Razonable. 2003. Cytomegalovirus infection after organ transplantation, p. 298-325. In R. A. Bowden, P. Ljungman, and C. V. Paya (ed.), Transplant infections. Lippincott Williams & Wilkins, Philadelphia, PA.
14. Potena, L., C. T. Holweg, C. Chin, H. Luikart, D. Weisshaar, B. Narasimhan, W. F. Fearon, D. B. Lewis, J. P. Cooke, E. S. Mocarski, and H. A. Valantine. 2006. Acute rejection and cardiac allograft vascular disease are reduced by suppression of subclinical cytomegalovirus infection. Transplantation 82: 398-405.
15. Razonable, R. R., R. A. Brown, J. Wilson, C. Groettum, W. Kremers, M. Espy, T. F. Smith, and C. V. Paya. 2002. The clinical use of various blood compartments for cytomegalovirus (CMV) DNA quantitation in transplant recipients with CMV disease. Transplantation 73:968-973.
16. Razonable, R. R., A. Rivero, A. Rodriguez, J. Wilson, J. Daniels, G. Jenkins, T. Larson, W. C. Hellinger, J. R. Spivey, and C. V. Paya. 2001. Allograft rejection predicts the occurrence of late-onset cytomegalovirus (CMV) disease among CMV-mismatched solid organ transplant patients receiving prophylaxis with oral ganciclovir. J. Infect. Dis. 184:1461-1464.
17. Rubin, R. H. 2000. Prevention and treatment of cytomegalovirus disease in heart transplant patients. J. Heart Lung Transplant. 19:731-735.
18. Shirali, G. S., J. Ni, R. E. Chinnock, J. K. Johnston, G. L. Rosenthal, N. E. Bowles, and J. A. Towbin. 2001. Association of viral genome with graft loss in children after cardiac transplantation. N. Engl. J. Med. 344:1498-1503.
19. Sissons, J. G., M. Bain, and M. R. Wills. 2002. Latency and reactivation of human cytomegalovirus. J. Infect. 44:73-77.
20. Slobedman, B., and E. S. Mocarski. 1999. Quantitative analysis of latent human cytomegalovirus. J. Virol. 73:4806-4812.
21. Stassen, F. R., X. Vega-Cordova, I. Vliegen, and C. A. Bruggeman. 2006. Immune activation following cytomegalovirus infection: more important than direct viral effects in carsiovascular disease? J. Clin. Virol. 35:349-353.
22. Tu, W., L. Potena, P. Stepick-Biek, L. Liu, K. Y. Dionis, H. Luikart, W. F. Fearon, T. H. Holmes, H. A. Valantine, E. S. Mocarski, and D. B. Lewis. 2006. T-cell immunity to subclinical cytomegalovirus infection limits cardiac allograft disease. Circulation 114:1608-1615.
23. Valantine, H. A. 2004. The role of viruses in cardiac allograft vasculopathy. Am. J. Transplant. 4:169-177.
24. Valantine, H. A., S. Z. Gao, S. G. Menon, D. G. Renlund, S. A. Hunt, P. Oyer, E. B. Stinson, B. W. Brown, Jr., T. C. Merigan, and J. S. Schroeder. 1999. Impact of prophylactic immediate posttransplant ganciclovir on development of transplant atherosclerosis: a post hoc analysis of a randomized, placebo-controlled study. Circulation 100:61-66.
25. Valantine, H. A., H. Luikart, R. Doyle, J. Theodore, S. Hunt, P. Oyer, R. Robbins, G. Berry, and B. Reitz. 2001. Impact of cytomegalovirus hyperimmune globulin on outcome after cardiothoracic transplantation: a comparative study of combined prophylaxis with CMV hyperimmune globulin plus ganciclovir versus ganciclovir alone. Transplantation 72:1647-1652.